Department of Neurology, The Jikei University School of Medicine, Tokyo, Japan.
Department of Rehabilitation Medicine, The Jikei University School of Medicine, Tokyo, Japan.
J Neurol Sci. 2024 Jul 15;462:123069. doi: 10.1016/j.jns.2024.123069. Epub 2024 May 28.
Although high-frequency repetitive transcranial magnetic stimulation (HF-rTMS) has shown benefits in chronic stroke, its application in subacute ischemic stroke remains underexplored. This study aims to investigate the effects and safety of lesion-side HF-rTMS in subacute ischemic stroke.
Prospective lesion-side HF-rTMS was conducted on consecutive ischemic stroke patients within 3 days of onset from February 2019 to June 2022. Inclusion criteria required persistent paralysis (NIHSS score ≥ 1 for at least 7 days). Exclusion criteria comprised cortical infarction, disturbance of consciousness, and age over 80 years. A conventional rehabilitation group meeting the same criteria from June 2015 to January 2019 served as a comparison. We compared the two groups regarding clinical background and outcome. We also evaluated incidence of epilepsy and exacerbation of the NIHSS score in the rTMS group.
Seventy-eight patients participated, with 50% in the HF-rTMS group. Median time from onset to HF-rTMS initiation was 9 (IQR 7-12) days. A favorable outcome (modified Rankin Scale score 0-2) at 3 months was more frequent in the rTMS group (80% vs. 44%, p = 0.002). HF-rTMS was independently associated with a favorable outcome at 3 months (OR = 5.60, 95% CI = 1.53-20.50, p = 0.009). No cases of epilepsy or exacerbation of NIHSS score were observed.
HF-rTMS demonstrates potential effectiveness and safety in subacute ischemic stroke patients.
尽管高频重复经颅磁刺激(HF-rTMS)已显示出在慢性中风中的益处,但在亚急性缺血性中风中的应用仍未得到充分探索。本研究旨在探讨病灶侧 HF-rTMS 在亚急性缺血性中风中的作用和安全性。
前瞻性病灶侧 HF-rTMS 对 2019 年 2 月至 2022 年 6 月发病后 3 天内的连续缺血性中风患者进行。纳入标准为持续性瘫痪(NIHSS 评分至少为 7 天)。排除标准包括皮质梗死、意识障碍和年龄超过 80 岁。从 2015 年 6 月至 2019 年 1 月,符合相同标准的常规康复组作为对照。我们比较了两组的临床背景和结果。我们还评估了 rTMS 组癫痫和 NIHSS 评分恶化的发生率。
78 名患者参与了研究,其中 HF-rTMS 组占 50%。从发病到 HF-rTMS 开始的中位数时间为 9 天(IQR 7-12)。rTMS 组 3 个月时的良好预后(改良 Rankin 量表评分 0-2)更为常见(80% vs. 44%,p=0.002)。HF-rTMS 与 3 个月时的良好预后独立相关(OR=5.60,95%CI=1.53-20.50,p=0.009)。未观察到癫痫或 NIHSS 评分恶化的病例。
HF-rTMS 对亚急性缺血性中风患者具有潜在的有效性和安全性。